Menopausia

Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73. Resumen

Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9.Texto completo  Resumen

North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021 Sep 1;28(9):973-97. Resumen

The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-94. Resumen

Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 17;(1):CD004143.Texto completo  Resumen

Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials. JAMA. 2017 Sep 12;318(10):927-38. Resumen

1. National Institute for Health and Care Excellence. Menopause: diagnosis and management. Dec 2019 [internet publication].Texto completo

2. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 2006 Nov 30;355(22):2338-47.Texto completo  Resumen

3. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73. Resumen

4. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9.Texto completo  Resumen

5. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000 Sep;96(3):351-8. Resumen

6. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000 May 15;61(10):3090-6.Texto completo  Resumen

7. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008 Mar;93(3):861-8.Texto completo  Resumen

8. North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021 Sep 1;28(9):973-97. Resumen

9. Tao XY, Zuo AZ, Wang JQ, et al. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric. 2016 Nov 17;19(1):27-36. Resumen

10. Cífková R, Krajčoviechová A. Dyslipidemia and cardiovascular disease in women. Curr Cardiol Rep. 2015;17:609.Texto completo  Resumen

11. Maas AHEM, Rosano G, Cifkova R, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J. 2021 Mar 7;42(10):967-84.Texto completo  Resumen

12. Palacios S, Henderson VW, Siseles N, et al. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric. 2010 Oct;13(5):419-28. Resumen

13. Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Womens Health. 2014 Feb 20;6:235-43.Texto completo  Resumen

14. Kinney A, Kline J, Levin B. Alcohol, caffeine and smoking in relation to age at menopause. Maturitas. 2006 Apr 20;54(1):27-38. Resumen

15. Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014 Feb;132(2):428-33. Resumen

16. US Preventive Services Task Force. Hormone therapy in postmenopausal persons: primary prevention of chronic conditions. Nov 2022 [internet publication].Texto completo  Resumen

17. The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-94. Resumen

18. Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 17;(1):CD004143.Texto completo  Resumen

19. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 565: hormone therapy and heart disease. Jun 2013 [internet publication].Texto completo  Resumen

20. Kremer C, Gdovinova Z, Bejot Y, et al. European Stroke Organisation guidelines on stroke in women: Management of menopause, pregnancy and postpartum. Eur Stroke J. 2022 Jun;7(2):I-XIX.Texto completo  Resumen

21. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020 Dec 22;142(25):e506-32.Texto completo  Resumen

22. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019 Jan 9;364:k4810.Texto completo  Resumen

23. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause - 2017 update. Endocr Pract. 2017 Jul;23(7):869-80.Texto completo  Resumen

24. LaMonte MJ, Wactawski-Wende J, Larson JC, et al. Association of physical activity and fracture risk among postmenopausal women. JAMA Netw Open. 2019 Oct 2;2(10):e1914084.Texto completo  Resumen

25. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Nov 2023 [internet publication].Texto completo

26. Taylor SM, Kinney AM, Kline JK. Menopausal transition: predicting time to menopause for women 44 years or older from simple questions on menstrual variability. Menopause. 2004 Jan-Feb;11(1):40-8. Resumen

27. Shifren JL, Gass ML. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014 Oct;21(10):1038-62. Resumen

28. Rödström K, Bengtsson C, Lissner L, et al. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause. 2002 May-Jun;9(3):156-61. Resumen

29. North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause. 2013 Sep;20(9):888-902.Texto completo  Resumen

30. Duckitt K. Managing perimenopausal menorrhagia. Maturitas. 2010 Jul;66(3):251-6. Resumen

31. Goodman NF, Cobin RH, Ginzburg SB, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. Endocr Pract. 2011 Nov-Dec;17(6):949-54. Resumen

32. Cramer H, Lauche R, Langhorst J, et al. Effectiveness of yoga for menopausal symptoms: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2012 Nov 7;2012:863905.Texto completo  Resumen

33. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin no. 141: management of menopausal symptoms. Jan 2014 [internet publication].Texto completo  Resumen

34. Hamoda H, Panay N, Peddar H, et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. 2020 [internet publication].Texto completo

35. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 Nov;100(11):3975-4011.Texto completo  Resumen

36. Archer DF, Pickar JH, MacAllister DC, et al. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause. 2012 Jun;19(6):622-9. Resumen

37. Kovács G, Zelei T, Vokó Z. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis. Climacteric. 2016 Oct;19(5):488-95. Resumen

38. Tella SH, Gallagher JC. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause. Expert Opin Pharmacother. 2013 Dec;14(17):2407-20. Resumen

39. Valera MC, Gourdy P, Trémollières F, et al. From the Women's Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition. Maturitas. 2015 Nov;82(3):274-7. Resumen

40. Gaudard AM, Silva de Souza S, Puga ME, et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database Syst Rev. 2016 Aug 1;(8):CD010407.Texto completo  Resumen

41. American College of Obstetricians and Gynecologists. ACOG clinical consensus no. 6: compounded bioidentical menopausal hormone therapy. Nov 2023 [internet publication].Texto completo

42. Stuenkel CA, Manson JE. Compounded bioidentical hormone therapy: the national academies weigh in. JAMA Intern Med. 2021 Mar 1;181(3):370-71. Resumen

43. Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016 Aug;19(4):316-28.Texto completo  Resumen

44. Whelan AM, Jurgens TM, Trinacty M. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Pharmacother. 2013 Jan;47(1):112-6. Resumen

45. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials. JAMA. 2017 Sep 12;318(10):927-38. Resumen

46. de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2013 Apr;16(2):203-4.Texto completo  Resumen

47. de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016 Aug;19(4):313-5. Resumen

48. Medicines and Healthcare products Regulatory Agency. Drug safety update. Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping. Aug 2019 [internet publication].Texto completo

49. Beral V, Gaitskell K, Hermon C, et al.; Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015 May 9;385(9980):1835-42. Resumen

50. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019 Aug 29;394(10204):1159-68.Texto completo  Resumen

51. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. Oct 2005 [internet publication].Texto completo

52. British Menopause Society. BMS response to Lancet paper on the link between different forms of HRT and breast cancer incidence. Aug 2019 [internet publication].Texto completo

53. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006 May 3;295(17):2057-71. Resumen

54. The North American Menopause Society Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023 Jun 1;30(6):573-90. Resumen

55. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011 Jan 19;305(3):267-74.Texto completo  Resumen

56. American Academy of Family Physicians. ACOG releases clinical guidelines on management of menopausal symptoms. Am Fam Physician. 2014 Sep 1;90(5):338-40.Texto completo

57. Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014 Jan;29(1):204-13. Resumen

58. Orleans RJ, Li L, Kim MJ, et al. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med. 2014 May 8;370(19):1777-9.Texto completo  Resumen

59. Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014 Jul;174(7):1058-66.Texto completo  Resumen

60. Pinkerton JV, Archer DF, Guico-Pabia CJ, et al. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause. 2013 Jan;20(1):38-46. Resumen

61. Archer DF, Pinkerton JV, Guico-Pabia CJ, et al. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause. 2013 Jan;20(1):47-56. Resumen

62. Hayes LP, Carroll DG, Kelley KW. Use of gabapentin for the management of natural or surgical menopausal hot flashes. Ann Pharmacother. 2011 Mar;45(3):388-94. Resumen

63. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994 Jan;12(1):155-8. Resumen

64. Rahn DD, Carberry C, Sanses TV, et al.; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014 Dec;124(6):1147-56. Resumen

65. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018 Jan;25(1):11-20. Resumen

66. European Medicines Agency. Four-week limit for use of high-strength estradiol creams. Press release. Oct 2019 [internet publication].Texto completo

67. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016 Aug 31;(8):CD001500.Texto completo  Resumen

68. Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013 Jun;20(6):623-30. Resumen

69. Palacios S, Cancelo MJ. Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. Int J Womens Health. 2016 Oct 26;8:617-26.Texto completo  Resumen

70. Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3647-61. Resumen

71. Del Carmen MG, Rice LW. Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol. 2017 Aug;146(2):427-35. Resumen

72. O'Donnell RL, Clement KM, Edmondson RJ. Hormone replacement therapy after treatment for a gynaecological malignancy. Curr Opin Obstet Gynecol. 2016 Feb;28(1):32-41. Resumen

73. Goetsch MF, Lim JY, Caughey AB. Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial. Obstet Gynecol. 2014 Jun;123(6):1231-6. Resumen

74. Reid R, Abramson BL, Blake J, et al. Managing menopause. J Obstet Gynaecol Can. 2014 Sep;36(9):830-3.Texto completo  Resumen

75. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014 Oct;99(10):3489-510.Texto completo  Resumen

76. Dumoulin C, Cacciari LP, Hay‐Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018 Oct 4;(10):CD005654.Texto completo

77. Capobianco G, Donolo E, Borghero G, et al. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2012 Feb;285(2):397-403. Resumen

78. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med. 2005 May;23(2):117-25. Resumen

79. Spark MJ, Willis J. Systematic review of progesterone use by midlife and menopausal women. Maturitas. 2012 Jul;72(3):192-202. Resumen

80. Gordon JL, Girdler SS. Hormone replacement therapy in the treatment of perimenopausal depression. Curr Psychiatry Rep. 2014 Dec;16(12):517. Resumen

81. Veerus P, Hovi SL, Sevón T, et al. The effect of hormone therapy on women's quality of life in the first year of the Estonian Postmenopausal Hormone Therapy trial. BMC Res Notes. 2012 Apr 3;5:176.Texto completo  Resumen

82. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):309-18.Texto completo  Resumen

83. Maki PM, Kornstein SG, Joffe H, et al; Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018 Oct;25(10):1069-85.Texto completo  Resumen

84. Cohen LS, Soares CN, Joffe H. Diagnosis and management of mood disorders during the menopausal transition. Am J Med. 2005 Dec 19;118(suppl 12B):93-7. Resumen

85. Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013 Dec 10;(12):CD001395.Texto completo  Resumen

86. Sacks FM, Lichtenstein A, Van Horn L, et al; American Heart Association Nutrition Committee. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006 Feb 21;113(7):1034-44.Texto completo  Resumen

87. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016 Mar;23(3):243-56. Resumen

88. Scheffers CS, Armstrong S, Cantineau AE, et al. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015 Jan 22;1:CD011066.Texto completo  Resumen

89. Kontos M, Agbaje OF, Rymer J, et al. What can be done about hot flushes after treatment for breast cancer? Climacteric. 2010 Feb;13(1):4-21.Texto completo  Resumen

90. Walega DR, Rubin LH, Banuvar S, et al. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women. Menopause. 2014 Aug;21(8):807-14.Texto completo  Resumen

91. Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016 Oct 12;(10):CD008536.Texto completo  Resumen

92. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008 Aug 14;359(7):697-708.Texto completo  Resumen

93. O'Kelly AC, Michos ED, Shufelt CL, et al. Pregnancy and reproductive risk factors for cardiovascular disease in women. Circ Res. 2022 Feb 18;130(4):652-72.Texto completo  Resumen

94. Wenger NK, Lloyd-Jones DM, Elkind MSV, et al. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association. Circulation. 2022 Jun 7;145(23):e1059-71.Texto completo  Resumen